Aratana Therapeutics to Participate in Two Upcoming Investor Conferences

KANSAS CITY, Kan., May 15, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that it will participate in two upcoming investor conferences. 

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, will provide an overview of the Company's business during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event:


Stifel 2015 Dental & Veterinary Conference

Date: 


Wednesday, May 27, 2015

Time: 


8:35 am (Eastern Time)

Location:


The Peninsula Hotel, New York, NY




Event:


Jefferies 2015 Healthcare Conference

Date: 


Tuesday, June 2, 2015

Time: 


11:30 am (Eastern Time)

Location:


New York, NY

The presentation for the Jefferies 2015 Healthcare Conference will be webcast live and will remain available for 30 days following the presentation.  However, Aratana's presentation during the Stifel 2015 Dental and Veterinary Conference will not be webcast.  To access the Jefferies webcast, please visit the investor relations section of the Aratana website at aratana.investorroom.com.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts:

For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
ctooman@aratana.com; (913) 353-1026

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.

print email rss